You are here

February 2010

Features

A retrospective review was conducted to assess the effect of various interventions on inappropriate prescribing of acid-suppressive agents in the hospital. ­Providing educational lectures was helpful, but adding a pharmacist to the health care team resulted in the greatest decline in inappropriate use of these drugs.
Randolph E. Regal, BS, PharmD; Amanda D. Osta, MD; and Vikas I. Parekh, MD
Implications for Prescribing Practice and Therapeutic Interchange
Although low-molecular-weight heparins (LMWHs) have similar antithrombotic effects, they differ in their pharmacological and biochemical profiles. The authors discuss therapeutic interchange programs for currently available LMWHs and the risks to patients when agents are not clinically interchangeable.
Geno J. Merli, MD, and James B. Groce, PharmD
Meeting Highlights
Drugs discussed include dasatinib (Sprycel), nilotinib (Tasigna), and imatinib (Gleevec) for patients with chronic myelogenous leukemia; deferasirox (Exjade) for beta-thalassemia major with iron overload; eculizumab (Soliris) for thrombocytopenia; and romiplostim (Nplate) for myelodysplastic syndromes.
Walter Alexander
Topics include an influenza vaccine (Fluzone High-Dose) to prevent virus subtypes A and B in older patients; von Willebrand factor/coagulation factor VIII complex (Wilate) to treat spontaneous and trauma-induced bleeding in patients with von Willebrand’s disease; and tranexamic acid (Lysteda) for heavy menstrual bleeding.
Marvin M. Goldenberg, PhD, RPh, MS

Departments

Editorial
David B. Nash, MD, MBA, ­discusses the impact of health care reform on academic departments of medicine and their affiliated training programs.
David B. Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, explains how to ensure safety and minimize risks when oral tablets need to be split.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses the FDA’s plans to simplify the labeling of consumer medical information.
Stephen Barlas
From Actemra to Wilate, P&T presents the latest studies and information about FDA approvals, drug indications, product recalls, and industry updates.
Drug Forecast
Dr. Avena-Woods and Dr. Hilas review febuxostat (Uloric) for the treatment of gout.
Carmela Avena-Woods, PharmD, and Olga Hilas, PharmD, MPH, BCPS, CGP